CTO-PCI Technology for Heart Health in Egypt
The article from the Egypt Healthcare Authority (EHA) discusses the successful implementation and benefits of using CTO-PCI (Chronic Total Occlusion Percutaneous Coronary Intervention) technology to treat chronic coronary artery occlusion in Egypt. Here are some key points to consider:
- Success of Procedures: The EHA reported the successful treatment of three elderly patients (all over 60 years old) using CTO-PCI technology with micro-catheters and specialised wires at the International Medical Complex in Luxor. The procedures achieved a 100% success rate.
- Cost and Universal Health Coverage: The cost of CTO-PCI procedures outside the universal health coverage system exceeds 500,000 Egyptian pounds. However, under the universal health insurance system, patients contribute no more than 400 EGP.
- Medical Team and Expertise: The procedures were conducted by a highly skilled team of medical consultants, including top professors, cardiologists, and specialised nursing and technical staff. Key team members included Dr. Tarek Rashid, Head of the Scientific Committee for Cardiology, and Dr. Zein El-Abidin Abdel-Latif, Head of the Cardiology and Catheterization Department.
- Commitment to Innovation: The EHA emphasised its commitment to innovation and continuous development, adopting the latest global medical advances and introducing cutting-edge technologies across all medical specialties, particularly in cardiology.
- Patient Benefits: The patients treated were suffering from angina and severe pain due to coronary artery occlusion. The use of CTO-PCI technology significantly improved their quality of life.
- Healthcare Model: The EHA aims to provide a modern healthcare model in Egypt by ensuring access to the latest global medical advancements and maintaining a team of expert consultants.
This initiative reflects the Authority‘s dedication to providing innovative medical technologies and achieving high-quality care for patients under the universal health insurance system.
Recent Posts
Integration of Comparative Effectiveness Research into Drug Pricing Frameworks
Contemporary comparative effectiveness research plays a vital role in supporting federal and state drug pricing programs by highlighting real-world benefits, yet persistent challenges and unclear guidance continue to limit its integration. Core principles of evidence evaluation, research question...
European Pharmacists Preparation for Health Crisis Response
European pharmacists preparation ensures that community networks remain operational during health crises, enabling continuous patient care amid pandemics and infrastructure failures. The recently published PGEU position paper outlines seven priorities that integrate pharmacies into governance str...
Imfinzi Bladder Cancer Approval Marks Breakthrough in Immunotherapy
The Imfinzi bladder cancer approval by the FDA now offers a new immunotherapy option for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer when combined with standard BCG induction and maintenance therapy. This Imfinzi bladder cancer approval stems from the POTOMAC Phase III ...